Patient Square Capital to Acquire Patterson Companies in $4.1 Billion Oral Healthcare Deal

A RMB 30 billion M&A deal emerges in the oral care sector.

Recently, healthcare investment firm Patient Square Capital (hereinafter referred to as “Patient Square”) reached a definitive acquisition agreement with Patterson Companies, Inc. (hereinafter referred to as “Patterson”), a distributor of dental and animal health products. Under the terms of the agreement, Patient Square will acquire Patterson for $31.25 per share (approximately RMB 228.75), representing a total transaction value of approximately $4.1 billion (approximately RMB 30.012 billion).

The transaction is expected to be completed through committed equity financing provided by Patient Square and committed debt financing led by Citibank, UBS Investment Bank, and Wells Fargo Securities. The deal is anticipated to close in the fourth quarter of Patterson’s fiscal year 2025, at which point Patterson will become a privately held company and its common stock will be delisted from the U.S. stock exchanges.

Notably, the transaction includes a 40-day “go-shop” period, during which Patterson Companies may actively seek alternative acquisition proposals. It is worth noting that Patient Square’s offer in this transaction represents a 45% premium over the weighted average share price of Patterson Companies during the 30 trading days prior to its announcement of the evaluation of strategic alternatives.

So, why did Patient Square choose to acquire Patterson at a premium? And as a target worthy of such a premium acquisition, why did Patterson “submit” to another party?

Founded in 1877, Patterson is a global leader in the distribution of dental and animal health products, primarily providing dental and animal health products, technologies, and innovative business solutions to dental clinics, hospitals, veterinary clinics, and other healthcare institutions in the United States, Canada, and other regions.

Its dental business primarily comprises consumables, equipment, and related value-added services. Currently, Patterson Companies serves 200,000 dentists in the United States and 25,000 in Canada. As early as 2015, media outlets referred to it as “the second-largest dental supplier in the United States.”

Even so, Patterson Companies has encountered profitability challenges. In 2024, the company generated total revenue of $6.588 billion, a year-on-year increase of 1.5%. However, due to rising raw material costs and transportation expenses, its net profit for the same period amounted to only $186 million, representing a 10.2% year-on-year decline. The sluggish revenue growth coupled with the drop in net profit prompted Patterson Companies to pursue acquisitions “to protect shareholders’ interests.”

The other party to this transaction, Patient Square, is a highly renowned investment firm in the pharmaceutical and healthcare sector in recent years.

Patient Square was founded by Jim Momtazee, the former head of KKR’s healthcare division. During his 21-year tenure at KKR, he helped establish the firm’s healthcare business and its subsidiary group, and led or participated in numerous high-profile mergers and acquisitions in the healthcare sector.

For example, KKR, together with Merrill Lynch and Bain Capital, invested approximately $4.5 billion in equity and $18.5 billion in leveraged financing to acquire HCA, then the largest hospital operator in the United States. When including HCA’s existing debt at the time, the total transaction value reached $33 billion, making it the third-largest private equity buyout on record as of February 2023.

In 2020, Jim Momtazee founded Patient Square, and at the beginning of 2023, it completed its first fund raise, exceeding expectations by reaching $3.9 billion. This was the largest private equity fund in terms of initial capital raised globally as of February 2023.

Since then, Patient Square has officially embarked on its investment journey in the healthcare sector. Spanning from medical care to medical devices, diagnostics and life science tools, and healthcare services, Patient Square’s investment portfolio covers the entire healthcare industry across all stages.

This acquisition of Patterson Companies marks Patient Square’s first “investment” in the dental sector. Consequently, some industry observers believe this move will help Patient Square mitigate regulatory risks and ultimately complete the acquisition of Patterson Companies.

Regarding this transaction, Patterson CEO Don Zurbay stated, “The announcement of the transaction marks an exciting next step in Patterson’s development. We have delivered direct and certain value to Patterson’s shareholders. We conducted a rigorous review of the acquisition proposal to maximize our value and ensure that Patterson can continue to execute its strategic plans in the future.”

Jim Momtazee stated, “For decades, I have closely followed Patterson and have always admired the value it delivers to its partners and customers. Patient Square is pleased to work closely with Patterson to usher in a new chapter of growth for the company, building upon its long and proud legacy.”

Industry insiders have pointed out that Patient Square’s premium acquisition of Patterson Companies signals a rebound in the global dental market.

Meanwhile, China’s dental care capital market is also heating up.

First, let’s look at mergers and acquisitions. In October 2024, Zhonghong Dental issued an announcement stating that its subsidiary would acquire equity stakes in multiple dental outpatient clinics for RMB 1.601 million, aiming to further optimize its market layout and enhance regional competitiveness.

In July 2024, Keen Dental released a revised acquisition announcement, proposing to purchase a 73.3333% equity stake in Huaifu Medical for RMB 16.194 million and a 73.3333% equity stake in Chenxing Medical for RMB 19.1366 million, thereby indirectly holding a 73.3333% equity stake in Yucheng Dental and Qihe Dental.

In the same month, Arrail Group entered into an investment agreement through its subsidiaries with Wuxi Shantong Hospital Management Co., Ltd., Wuxi Shanxing Tianxia Investment Partnership (Limited Partnership), and Wuxi Tongshan Stomatological Hospital Co., Ltd., thereby making Wuxi Tongshan Stomatological Hospital a non-wholly owned subsidiary of Arrail Group and Wuxi Tongshan Hospital Management Co., Ltd. a non-wholly owned subsidiary, thus acquiring ownership of nine dental clinics in Wuxi City and its surrounding areas.

While listed companies expand their business footprints through acquisitions, the primary market has also witnessed substantial financing rounds. Taking October 2024 as an example, Dingzhi Dental, a leading brand and expert in complex dental implantology, completed a Series A financing round amounting to hundreds of millions of yuan; Raysmile Intelligence, a provider of comprehensive 3D printing solutions for dentistry, secured over RMB 100 million in its Series A financing; and Jingmei Medical, which focuses on the R&D, production, and sales of dental handpieces, also obtained nearly RMB 100 million in its Series A financing.

It is evident that these capital-favored companies, despite operating in different niche sectors, are all deeply cultivating their differentiated competitive advantages. For instance, Dingzhi Dental has specialized in complex dental implantology by developing the VIIV patented implant technology. This technique leverages the unique anatomical structures of the zygoma and pterygoid plates for implant placement, thereby significantly shortening treatment time and reducing surgical trauma. To date, Dingzhi Dental has performed immediate implantation and immediate loading for over 10,000 patients with severe alveolar bone defects, enabling normal function on the day of the procedure.

Reisai Intelligence has anchored itself in the rapidly growing field of 3D printing, leveraging applications in basic industrial design, consumer electronics and electrical appliances, digital dentistry, and science education and cultural creativity. The company has launched multiple 3D printing devices under its Shape, P, and Edge series, along with supporting software, more than 20 high-performance photosensitive resin materials, and end-user products, providing comprehensive product solutions and implementation services for diverse application scenarios.

These companies, with their more pronounced differentiated advantages, have attracted significant attention from the capital markets, indicating that the focus of the primary market has gradually shifted from pursuing scale to seeking innovation in technology and business models.

Overall, in 2024, domestically listed dental companies in China continued to expand their business scale through acquisitions, achieving resource aggregation. In the primary market, companies with innovative technologies and unique business models were more favored by capital. With enterprises intensifying their efforts to seek innovation, coupled with policy support and capital backing, the recovery of the dental market may accelerate.